高肿瘤突变负荷不能预测所有癌种的免疫检查点阻断反应
该研究利用癌症基因组图谱超过1万例肿瘤数据,比较TMB判定方法并分析预测新抗原负荷与CD8 T细胞的相关性。在CD8 T细胞水平与新抗原负荷正相关的癌种中,TMB-H肿瘤ORR为39.8%,显著高于TMB-L;但在无此相关性的癌种中,TMB-H肿瘤ORR仅15.3%,且低于TMB-L。分析未支持TMB-H作为所有实体瘤ICB治疗的生物标志物。
要点
- TMB-H预测ICB反应因癌种而异,并非所有实体瘤通用。
- CD8 T细胞与新抗原负荷正相关的癌种中,TMB-H者ORR达39.8%。
- 无此相关性的癌种中,TMB-H者ORR仅15.3%,且低于TMB-L。
核心结论
- 分析未支持将TMB-H作为所有实体瘤ICB治疗的生物标志物,需按癌种进一步研究。
研究设计与样本
- 基于癌症基因组图谱超过1万例患者肿瘤数据,比较TMB判定方法并分析预测新抗原负荷与CD8 T细胞的相关性。
- 通过客观缓解率(ORR,N=1551)和总生存期(OS,N=1936)分析TMB与ICB治疗结局的关联。
主要发现
- 在黑色素瘤、肺癌和膀胱癌等CD8 T细胞水平与新抗原负荷正相关的癌种中,TMB-H肿瘤ORR为39.8%(95%CI 34.9-44.8),显著高于TMB-L肿瘤(OR=4.1,95%CI 2.9-5.8,P<2×10-16)。
- 在乳腺癌、前列腺癌和胶质瘤等无此相关性的癌种中,TMB-H肿瘤ORR为15.3%(95%CI 9.2-23.4,P=0.95),未达20%,且显著低于TMB-L肿瘤(OR=0.46,95%CI 0.24-0.88,P=0.02)。
- 所评估患者队列中,两类肿瘤的总体ORR差异不显著(P=0.10)。
- 分析OS或将TMB作为连续变量处理得到等效结果。
临床怎么用
- 临床不应在所有实体瘤中仅凭TMB-H选择ICB治疗,应结合癌种类型及CD8 T细胞与新抗原负荷的相关性综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer approval of ICB treatment for any TMB-H tumor, as assessed by the targeted FoundationOne CDx assay in nine tumor types, the utility of this biomarker has not been fully demonstrated across all cancers. PATIENTS AND METHODS: Data from over 10 000 patient tumors included in The Cancer Genome Atlas were used to compare approaches to determine TMB and identify the correlation between predicted neoantigen load and CD8 T cells. Association of TMB with ICB treatment outcomes was analyzed by both objective response rates (ORRs, N = 1551) and overall survival (OS, N = 1936). RESULTS: In cancer types where CD8 T-cell levels positively correlated with neoantigen load, such as melanoma, lung, and bladder cancers, TMB-H tumors exhibited a 39.8% ORR to ICB [95% confidence interval (CI) 34.9-44.8], which was significantly higher than that observed in low TMB (TMB-L) tumors [odds ratio (OR) = 4.1, 95% CI 2.9-5.8, P < 2 × 10-16]. In cancer types that showed no relationship between CD8 T-cell levels and neoantigen load, such as breast cancer, prostate cancer, and glioma, TMB-H tumors failed to achieve a 20% ORR (ORR = 15.3%, 95% CI 9.2-23.4, P = 0.95), and exhibited a significantly lower ORR relative to TMB-L tumors (OR = 0.46, 95% CI 0.24-0.88, P = 0.02). Bulk ORRs were not significantly different between the two categories of tumors (P = 0.10) for patient cohorts assessed. Equivalent results were obtained by analyzing OS and by treating TMB as a continuous variable. CONCLUSIONS: Our analysis failed to support application of TMB-H as a biomarker for treatment with ICB in all solid cancer types. Further tumor type-specific studies are warranted.
引用
- McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021. PMID: 33736924. doi:10.1016/j.annonc.2021.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。